ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPH) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 84,900 shares, a decline of 27.1% from the January 15th total of 116,400 shares. Based on an average trading volume of 621,700 shares, the short-interest ratio is presently 0.1 days.

ProPhase Labs Stock Performance

PRPH traded down $0.02 during midday trading on Friday, hitting $0.33. 12,660,706 shares of the company were exchanged, compared to its average volume of 1,228,625. ProPhase Labs has a 1-year low of $0.22 and a 1-year high of $7.48. The firm’s 50 day moving average price is $0.55 and its 200-day moving average price is $1.54. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48.

Institutional Trading of ProPhase Labs

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. HighTower Advisors LLC increased its position in ProPhase Labs by 18.3% in the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after buying an additional 27,673 shares in the last quarter. Sheets Smith Wealth Management bought a new stake in ProPhase Labs during the 4th quarter worth approximately $158,000. Geode Capital Management LLC increased its holdings in ProPhase Labs by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after purchasing an additional 13,590 shares in the last quarter. Renaissance Technologies LLC increased its holdings in ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after purchasing an additional 71,375 shares in the last quarter. Finally, Warberg Asset Management LLC bought a new stake in ProPhase Labs during the 4th quarter worth approximately $77,000. 9.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on ProPhase Labs in a report on Sunday, February 9th. They set a “sell” rating on the stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.